公开(公告)号：US20220227874A1

公开(公告)日：2022-07-21

申请号：US17586321

申请日：2022-01-27

申请人： Pfizer Inc.

发明人： Oi Kwan Wong ,  Joyce Ching Chou ,  Mathilde Brunnhilde Dusseaux ,  Julianne Smith ,  Barbra Johnson Sasu

IPC分类号： C07K16/28 ,  C07K14/47 ,  C07K14/725

摘要： The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.

公开(公告)号：US11365253B2

公开(公告)日：2022-06-21

申请号：US16614701

申请日：2018-06-08

申请人： Pfizer Inc. ,  Boston Medical Center Corporation

发明人： Stephen Berasi ,  Janet Elizabeth Buhlmann ,  Eric M. Bennett ,  Nathan Higginson-Scott ,  Huilan Gao ,  Zong Sean Juo ,  Stefano V. Gulla ,  Christine Huard ,  Sreekumar R. Kodangattil ,  Jian Li ,  Weining Lu ,  Xueping Fan ,  David J. Salant

IPC分类号： C07H21/04 ,  C12P21/06 ,  C12N15/87 ,  C12N1/20 ,  C12N15/74 ,  A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  A61P13/12 ,  C12N15/85

摘要： The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.

公开(公告)号：US20220184199A1

公开(公告)日：2022-06-16

申请号：US17601949

申请日：2020-04-06

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Isis Kanevsky ,  Farid Latif Khan ,  Charles Harold Jones ,  John Michael McLaughlin

IPC分类号： A61K39/09

摘要： The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

公开(公告)号：US20220184041A1

公开(公告)日：2022-06-16

申请号：US17533592

申请日：2021-11-23

申请人： Pfizer Inc.

发明人： Shawn Cabral ,  Daniel Paul Canterbury ,  Robert Lee Dow ,  Andrew Fensome ,  Magdalena Korczynska ,  Sophie Yvette Lavergne ,  Allyn Timothy Londregan ,  Vincent Mascitti ,  David Walter Piotrowski ,  Andre Shavnya ,  Meihua Mike Tu ,  Tao Wang ,  Hanna Maria Wisniewska

IPC分类号： A61K31/428 ,  C07D417/04 ,  C07D513/04 ,  A61K31/437 ,  A61K31/353 ,  A61K31/423 ,  A61K31/415 ,  A61K31/192 ,  A61K31/12 ,  A61K31/7105

摘要： This application includes a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein the variables R1a, R1b, R2, R3, X, Y and Z are as defined herein, pharmaceutical compositions comprising the compounds of Formula I and methods of treatment comprising administering to a patient in need thereof a compound of Formula I for the treatment of transthyretin amyloidosis and diseases related thereto.

公开(公告)号：US20220168293A1

公开(公告)日：2022-06-02

申请号：US17538919

申请日：2021-11-30

申请人： PFIZER INC.

发明人： Despoina Thomaidou

IPC分类号： A61K31/4439 ,  C07K16/28 ,  A61P35/00

摘要： This invention relates to a method of managing an adverse event in a renal cell carcinoma (RCC) patient undergoing treatment with axitinib, or a pharmaceutically acceptable salt thereof, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 1-7 days to allow the adverse event to resolve before restarting treatment. Additionally, the invention relates to a method of managing an adverse event in an RCC patient undergoing treatment with a combination of axitinib, or a pharmaceutically acceptable salt thereof, and an immune-oncology (IO) agent, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 4-11 days to allow the adverse event to resolve before restarting axitinib, or a pharmaceutically acceptable salt thereof, treatment.

公开(公告)号：US20220142927A1

公开(公告)日：2022-05-12

申请号：US17580991

申请日：2022-01-21

申请人： PFIZER INC.

发明人： Scott Max Herbig ,  Sriram Krishnaswami ,  Joseph Kushner, IV ,  Manisha Lamba ,  Thomas C. Stock

IPC分类号： A61K9/20 ,  A61K31/519 ,  A61K9/00

摘要： The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

公开(公告)号：US20220136020A1

公开(公告)日：2022-05-05

申请号：US17431462

申请日：2020-02-20

申请人： Pfizer Inc.

发明人： Ling Chu ,  Scott Andrew Cook ,  Nishith Merchant ,  Justin Keith Moran

IPC分类号： C12P19/04 ,  B01D21/01 ,  B01D61/14 ,  B01D39/20

摘要： The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.

公开(公告)号：US20220125777A1

公开(公告)日：2022-04-28

申请号：US17427015

申请日：2020-01-31

申请人： Pfizer Inc.

发明人： Zhou Zhu ,  Yuan Liu

IPC分类号： A61K31/4545 ,  A61K31/4196 ,  A61K31/566 ,  A61K31/565 ,  A61K31/519 ,  A61P35/00

摘要： This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.

公开(公告)号：US11312713B2

公开(公告)日：2022-04-26

申请号：US16492558

申请日：2018-03-06

申请人： Pfizer Inc.

发明人： Michael Aaron Brodney ,  Thomas Allen Chappie ,  Jinshan Michael Chen ,  Jotham Wadsworth Coe ,  Karen Jean Coffman ,  Paul Galatsis ,  Michelle Renee Garnsey ,  Christopher John Helal ,  Jaclyn Louise Henderson ,  Bethany Lyn Kormos ,  Ravi G. Kurumbail ,  Luis Angel Martinez-Alsina ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Colin Richard Rose ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest ,  Travis T. Wager ,  Joseph Scott Warmus ,  Yuan Zhang

IPC分类号： C07D471/04

摘要： The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

公开(公告)号：US20220119545A1

公开(公告)日：2022-04-21

申请号：US17292257

申请日：2019-11-07

申请人： Beth Israel Deaconess Medical Center ,  Pfizer Inc. ,  Cornell University

发明人： Lewis C. CANTLEY ,  Stephen P. SOLTOFF ,  Brooke M. EMERLING ,  George POULOGIANNIS ,  Cindy M. HODAKOSKI ,  Hui LIU ,  Irina APOSTOLOU ,  Brian Gaither BATES ,  Kimberly Ann MARQUETTE ,  Eric M. BENNETT ,  Lidia MOSYAK ,  Lioudmila G. TCHISTIAKOVA ,  Edward Christian ROSFJORD ,  Isaac J. RONDON ,  Chao Bai HUANG

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.